3-MMC HCI Powder

3-MMC HCI Powder

3-MMC HCI Powder (3-MMC), also known as metaphedrone, is a designer drug from the substituted cathinone family.

3-MMC is a monoamine transporter substrate (a substance acted upon by monoamine transporters in the brain) that potently releases and inhibits the reuptake of dopamine and norepinephrine, as well as displaying moderate serotonin releasing activity.

3-Methylmethcathinone is a structural isomer of mephedrone (4-methylmethcathinone), and as such is illegal via blanket bans in many countries that have banned mephedrone.

However, 3-MMC has still appeared on the recreational drug market as an alternative to mephedrone, and was first identified being sold in Sweden in 2012. Unlike some other synthetic cathinones, 3-MMC has been evaluated in at least one large mammal study.

3-MMC HCI Powder was first encountered in Sweden in 2012; it was created as a designer drug following the control in many countries of the related compound mephedrone.

It was sold as a research chemical, usually in powdered form. There is no known or reported medical use of 3-MMC; it is primarily used recreationally.

Side effects of 3-MMC include increased heart rate, increased blood pressure, and decreased appetite.
The toxicokinetics of 3-MMC HCI Powder are thought to be similar to those for mephedrone.

The first human study conducted in 14 healthy human volunteers concluded that “…low to moderate doses of 3-MMC were well tolerated and safe and that potential health risks might only occur at high or excessive doses of 3-MMC HCI Powder.